ArticleEndocrine, metabolic & immune disorders drug targets2026
Enhancement of Metformin's Efficacy by Betel Nut Polyphenols in Type 2 Diabetic Rats Exposed to High Altitude.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh-altitude environment inhibited the metabolism and increased the absorption of metformin in Type 2 Diabetes Mellitus (T2DM), but the therapeutic effect of metformin was impaired. This study aimed to investigate the effect of betel nut polyphenols (BP) on the therapeutic efficacy of metformin at high altitude.
methodsFirstly, we prepared the T2DM rat model by combining a high-sugar/high-fat diet with streptozotocin. For the pharmacokinetic (PK) study, 12 diabetic rats were randomly divided into the model + metformin (DMM) group and the DMM + BP (DMMB) group. Thirty-two diabetic rats were randomly divided into four groups for the pharmacodynamic (PD) study: model (DM) group, DM + metformin (DMM) group, DMM + high altitude (DMMH) group, and DMMH + BP (DMMHB) group, with the normal diet (DN) group as the control. Subsequently, fasting glucose, insulin resistance index (HOMA-IR), lactic acid (LA), pyruvate (PA), lactate dehydrogenase (LDH), oxidative stress, and inflammatory factors were measured in all groups.
resultsThe PK results showed that BP did not affect the PK behaviour of metformin DISCUSSION: The therapeutic effect of metformin was impaired in a high-altitude environment. This study confirmed that the beneficial effects of metformin were enhanced when it was co-administered with the anti-hypoxic drug BP in a high-altitude environment, providing a new therapeutic approach for treating diabetic patients in such environments.
conclusionBP obviously enhanced the therapeutic effect of metformin by improving the antioxidant capacity of T2DM rats in a high-altitude environment. Therefore, BP can serve as a potential adjuvant to enhance the beneficial effects of metformin in a high-altitude environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.